Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model.

Authors: Zhang, Y  Kurup, P  Xu, J  Carty, N  Fernandez, SM  Nygaard, HB  Pittenger, C  Greengard, P  Strittmatter, SM  Nairn, AC  Lombroso, PJ 
Citation: Zhang Y, etal., Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19014-9. doi: 10.1073/pnas.1013543107. Epub 2010 Oct 18.
Pubmed: (View Article at PubMed) PMID:20956308
DOI: Full-text: DOI:10.1073/pnas.1013543107

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder. Early in the pathophysiology of AD, synaptic function is disrupted by soluble Abeta oligomers, possibly through Abeta-mediated internalization of NMDA receptors. Striatal-enriched phosphatase (STEP) is a tyrosine phosphatase that regulates the internalization of NMDA receptors. Recent work shows that STEP is elevated in the prefrontal cortex of human AD patients and in animal models of AD. Here, we use genetic manipulations to reduce STEP activity in a triple transgenic AD mouse model and show that a decrease in STEP levels reverses cognitive and cellular deficits observed in these mice. Our results suggest that STEP inhibitors may prove therapeutic for this devastating disorder.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 9835007
Created: 2015-03-12
Species: All species
Last Modified: 2015-03-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.